Treatment News : Kaletra and Epivir Dual Therapy Works as Well as Triple Combo

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » October 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


October 23, 2013

Kaletra and Epivir Dual Therapy Works as Well as Triple Combo

Treating HIV with a dual regimen of Kaletra (lopinavir boosted with ritonavir) and Epivir (lamivudine) is as effective as a standard triple regimen of Kaletra plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), aidsmap reports. Researchers conducted an open-label Phase III study of 426 treatment-naive people with HIV and presented their findings at the 14th European AIDS Conference in Brussels.

The study participants were randomly assigned to take twice-daily Kaletra plus Epivir or to take Kaletra plus two NRTIs in a fixed-dose pill. Among those taking the two NRTIs, 9 percent took Epzicom (lamivudine/abacavir), 37 percent took Truvada (tenofovir/emtricitabine) and 54 percent took Combivir (lamivudine/zidovudine).

Eight percent of those in the double therapy group discontinued participation in the study, compared with 14 percent in the triple therapy group. Another 10 people left the study before beginning treatment. After 48 weeks of treatment, this left 88 percent of the group assigned to dual therapy reaching an undetectable viral load and 84 percent of the triple therapy group doing so. Looking just at those who completed treatment, a respective 96 and 97 percent of each group achieved an undetectable viral load. Each group also elevated its initial median CD4 count of 325 by a respective 227 and 217 cells.

Among those who began the study with high viral loads, 87 percent in the dual therapy arm and 78 percent in the triple therapy arm achieved an undetectable viral load.

Dual therapy appeared to lead to an improved side effect profile. One percent of that group discontinued the study early because of adverse side effects or death, compared with 5 percent of the triple therapy group. While both treatments were safe and well tolerated, 65 people taking dual therapy experienced grade 2 or 3 adverse side effects, compared with 88 in the triple therapy arm.

To read the aidsmap story, click here.

Search: Kaletra, dual combination, lopinavir, ritonavir, Epivir, lamivudine, NRTIs, aidsmap, 14th European AIDS Conference in Brussels, abacavir, Epzicome, Truvada, tenofovir, emtricitabine, Combivir, zidovudine.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.